𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Discrimination of normal, benign, and malignant breast tissues by Raman spectroscopy

✍ Scribed by M. V. P. Chowdary; K. Kalyan Kumar; Jacob Kurien; Stanley Mathew; C. Murali Krishna


Publisher
Wiley (John Wiley & Sons)
Year
2006
Tongue
English
Weight
482 KB
Volume
83
Category
Article
ISSN
0006-3525

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Breast cancers are the leading cancers among females. Diagnosis by fine needle aspiration cytology (FNAC) is the gold standard. The widely practiced screening method, mammography, suffers from high false positive results and repeated exposure to harmful ionizing radiation. As with all other cancers survival rates are shown to heavily depend on stage of the cancers (Stage 0, 95%; Stage IV, 75%). Hence development of more reliable screening and diagnosis methodology is of considerable interest in breast cancer management. Raman spectra of normal, benign, and malignant breast tissue show significant differences. Spectral differences between normal and diseased breast tissues are more pronounced than between the two pathological conditions, malignant and benign tissues. Based on spectral profiles, the presence of lipids (1078, 1267, 1301, 1440, 1654, 1746 cm^−1^) is indicated in normal tissue and proteins (stronger amide I, red shifted ΔCH~2~, broad and strong amide III, 1002, 1033, 1530, 1556 cm^−1^) are found in benign and malignant tissues. The major differences between benign and malignant tissue spectra are malignant tissues seem to have an excess of lipids (1082, 1301, 1440 cm^−1^) and presence of excess proteins (amide I, amide III, red shifted ΔCH~2~, 1033, 1002 cm^−1^) is indicated in benign spectra. The multivariate statistical tool, principal components analysis (PCA) is employed for developing discrimination methods. A score of factor 1 provided a reasonable classification of all three tissue types. The analysis is further finetuned by employing Mahalanobis distance and spectral residuals as discriminating parameters. This approach is tested both retrospectively and prospectively. The limit test, which provides the most unambiguous discrimination, is also considered and this approach clearly discriminated all three tissue types. These results further support the efficacy of Raman spectroscopic methods in discriminating normal and diseased breast tissues. © 2006 Wiley Periodicals, Inc. Biopolymers 83:556–569, 2006

This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at [email protected]


📜 SIMILAR VOLUMES


Discrimination of normal, inflammatory,
✍ R. Malini; K. Venkatakrishna; J. Kurien; Keerthilatha M. Pai; Lakshmi Rao; V. B. 📂 Article 📅 2006 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 407 KB

## Abstract Optical spectroscopy methods are fast emerging as potential alternatives for early diagnosis of cancer. A Raman spectroscopy method for discrimination of normal and malignant oral tissues has been developed by us earlier. It is necessary to evaluate and establish the validity of the app

Raman spectroscopy can differentiate mal
✍ Rachel E. Kast; Gulay K. Serhatkulu; Alex Cao; Abhilash K. Pandya; Houbei Dai; J 📂 Article 📅 2008 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 289 KB

## Abstract Raman spectroscopy shows potential in differentiating tumors from normal tissue. We used Raman spectroscopy with near‐infrared light excitation to study normal breast tissue and tumors from 11 mice injected with a cancer cell line. Spectra were collected from 17 tumors, 18 samples of ad

Study of FHIT transcripts in normal and
✍ Ivan Bièche; Alain Latil; Véronique Becette; Rosette Lidereau 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 207 KB 👁 2 views

Cytogenetic and molecular studies have suggested that the 3p14.2 chromosome subband contains tumor suppressor genes involved in the pathogenesis of many types of human cancers. Recently, the FHIT (fragile histidine triad) gene was identified in this part of chromosome 3 as a candidate suppressor gen

Concentrations of oestrone and 4-hydroxy
✍ M. J. Reed; G. W. Aherne; M. W. Ghilchik; S. Patel; J. Chakraborty 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 477 KB

## Abstract 4‐Hydroxyandrostenedione (4‐OHA) is a specific inhibitor of aromatase activity used for the treatment of breast cancer in post‐menopausal women. Treatment with 4‐OHA has been shown to inhibit the peripheral conversion of androstenedione to oestrone and reduce plasma oestrogen concentrat